PharmNovo AB is a clinical-stage pharmaceutical company developing PN6047, a drug candidate that selectively targets the delta opioid receptor to provide effective relief from neuropathic pain. Unlike conventional opioids, PN6047 has demonstrated safety and tolerability in Phase I trials, with no serious adverse events or common opioid-related side effects.
Funding
$16.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EAFounders
Product
Problem
Current treatments for neuropathic pain, such as medicines for epilepsy and depression or conventional opioids, are often inadequate, have significant side effects, and carry a risk of addiction. There is a need for new pain-relieving drugs explicitly developed for neuropathic pain.
Solution
PharmNovo is a clinical-stage pharmaceutical company developing PN6047, a selective delta opioid receptor agonist (DORA) for neuropathic pain. Unlike conventional opioids that affect the mu-receptor and cause side effects like respiratory depression and addiction, PN6047 selectively activates the delta receptor in the endogenous opioid system. This novel approach aims to provide effective pain relief without the adverse effects and abuse potential associated with traditional opioid treatments. PN6047 has demonstrated safety and tolerability in Phase I trials and is preparing for Phase II proof-of-concept studies.
Target Audience
The primary target audience includes individuals suffering from neuropathic pain, as well as healthcare providers, pain specialists, and pharmaceutical companies seeking safer and more effective pain management solutions.
Features
- Selective delta opioid receptor agonist (DORA)
- Does not affect the mu (μ) opioid receptor
- Demonstrated safety and tolerability in Phase I clinical trials
- No serious adverse events reported in Phase I trials
- No common opioid-related side effects observed (e.g., respiratory depression, constipation, itching, abuse potential)
- High selectivity and potency in preclinical studies
- Demonstrated efficacy in reducing neuropathic pain in animal models
- Potential to address associated anxiety and depression
- Fully drug-able properties enabling the production of a commercial solid dosage form